Zogenix, Inc. has entered an exclusive co-promotion agreement for Migranal (dihydroergotamine mesylate, USP) Nasal Spray in the U.S. Zogenix’s will begin selling Migranal to its customer base of prescribers in late July 2013. The initial term of the agreement will be through December 31, 2015, and can be extended. Valeant will record all product revenues and Zogenix will be compensated in the form of a quarterly service fee based on a percentage of sales. Migranal is indicated for the trea...